These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27180793)

  • 1. Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer.
    Nakai M; Takei H; Yanagihara K; Yamashita K; Uchida E
    J Nippon Med Sch; 2016; 83(2):81-6. PubMed ID: 27180793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
    Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
    Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
    Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
    Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
    Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
    Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
    Nakamura Y; Aono T; Nomura M; Iwase K; Tanaka Y
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2165-8. PubMed ID: 21084819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ethinylestradiol Following Everolimus plus Exemestane Was Effective in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer - A Case Report].
    Matsuoka A; Hirano A; Hattori A; Ogura K; Inoue H; Yukawa H; Sakaguchi S; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1219-1222. PubMed ID: 27760942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
    Shankar A; Roy S; Rath GK; Julka PK; Kamal VK; Malik A; Patil J; Jeyaraj PA; Mahajan MK
    Asian Pac J Cancer Prev; 2015; 16(15):6359-64. PubMed ID: 26434843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
    Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
    Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of metastatic breast cancer with liver metastasis effectively treated with capecitabine and vinorelbine].
    Inari H; Chiba A; Inaba M; Ino H; Fukahori M; Yoshida A
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):333-5. PubMed ID: 19223759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
    Macedo LF; Sabnis GJ; Goloubeva OG; Brodie A
    Cancer Res; 2008 May; 68(9):3516-22. PubMed ID: 18451180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-Term Effect of Fulvestrant for Locally Advanced Breast Cancer in an Elderly Patient - A Case Report].
    Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):76-78. PubMed ID: 29362313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Luo J; Naughton M; Ademuyiwa F; Suresh R; Griffith M; Griffith OL; Skidmore ZL; Spies NC; Ramu A; Trani L; Pluard T; Nagaraj G; Thomas S; Guo Z; Hoog J; Han J; Mardis E; Lockhart C; Ellis MJ
    Clin Cancer Res; 2016 Apr; 22(7):1583-91. PubMed ID: 26563128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
    Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
    Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
    Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
    Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
    Safra T; Greenberg J; Ron IG; Ben-Yosef R; Inbar M; Sarid D; Yaal-Hahoshen N
    Isr Med Assoc J; 2008 May; 10(5):339-43. PubMed ID: 18605354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
    Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
    Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.